DeepMed Research

Probenecid

Generic Name: Probenecid

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₉NO_₄S

CAS Number: 57-66-9

Unique Ingredient Identifier: PO572Z7917

Background: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.

Indication: For the reduction of serum uric acid concentrations in chronic gouty arthritis and tophaceous gout in patients with frequent disabling gout attacks. Has also been effectively used to promote uric acid excretion in hyperuricemia secondary to the administration of thiazide and related diuretics.

Associated Conditions: Bacterial Infections, Chronic Gouty Arthritis, Elevated Serum Uric Acid, Gout Chronic, Hyperuricemia, Infection

Clinical Trials

A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 690517 formulation 1
Drug: BI 690517 formulation 2
Drug: Probenecid

First Posted Date: 2024-10-18

Last Posted Date: 2025-01-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT06647810

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Rosuvastatin
Drug: Metformin
Drug: Digoxin
Drug: Povorcitinib
Drug: Probenecid

First Posted Date: 2024-05-16

Last Posted Date: 2025-02-06

Lead Sponsor: Incyte Corporation

Target Recruit Count: 71

Registration Number: NCT06416800

Locations: 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States

A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)

Phase 1

Completed

Conditions: Relative Bioavailability

Interventions: Drug: PanCytoVir™ 100 mg/mL oral suspension
Drug: Probenecid 500 mg

First Posted Date: 2023-09-06

Last Posted Date: 2024-11-21

Lead Sponsor: TrippBio, Inc.

Target Recruit Count: 14

Registration Number: NCT06025344

Locations: 🇮🇳
Vayam Research Solutions Limited, Gujrat, India

Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid

Phase 1

Completed

Conditions: Drug Drug Interaction

Interventions: Drug: Digoxin
Drug: Itraconazole
Drug: Rosuvastatin
Drug: ZSP1273
Drug: Probenecid

First Posted Date: 2023-07-20

Last Posted Date: 2024-01-29

Lead Sponsor: Guangdong Raynovent Biotech Co., Ltd

Target Recruit Count: 49

Registration Number: NCT05954624

Locations: 🇨🇳
The First Affiliated Hospital of Guangzhou University of Chinese medicine, Guangzhou, China

Improvement of Reproductive Function in Men With Spinal Cord Injury (SCI)

Phase 3

Recruiting

Conditions: Infertility, Male

Interventions: Drug: Probenecid 500 Milligrams (mg)
Drug: probenecid 250 Milligrams (mg)
Drug: Placebo

First Posted Date: 2023-06-15

Last Posted Date: 2025-01-16

Lead Sponsor: University of Miami

Target Recruit Count: 90

Registration Number: NCT05903859

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid

Recruiting

Conditions: Bacterial Infections
Oncologic Disease
Renal Excretion
Inflammatory Disease

Interventions: Combination Product: 11C-para-aminobenzoic acid PET/CT
Drug: Probenecid

First Posted Date: 2022-11-10

Last Posted Date: 2025-05-09

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 30

Registration Number: NCT05611905

Locations: 🇺🇸
Johns Hopkins Medical Institutions, Baltimore, Maryland, United States

Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Rongliflozin
Drug: Probenecid
Drug: Rifampin

First Posted Date: 2022-08-11

Last Posted Date: 2023-03-01

Lead Sponsor: Sunshine Lake Pharma Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT05497674

Locations: 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China

Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters

Early Phase 1

Recruiting

Conditions: Interaction
Endogenous Biomarkers

Interventions: Drug: Furosemide Oral Liquid Product
Drug: MetFORMIN Oral Solution
Drug: Cimetidine 400 MG
Drug: Probenecid 500 MG

First Posted Date: 2022-05-09

Last Posted Date: 2024-12-19

Lead Sponsor: Washington State University

Target Recruit Count: 32

Registration Number: NCT05365451

Locations: 🇺🇸
Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington, United States

AV-101 Alone and in Combination With Probenecid in Healthy Subjects

Phase 1

Conditions: Drug Drug Interaction

Interventions: Drug: AV-101
Drug: Probenecid

First Posted Date: 2022-03-15

Last Posted Date: 2022-03-15

Lead Sponsor: VistaGen Therapeutics, Inc.

Target Recruit Count: 24

Registration Number: NCT05280054

Locations: 🇺🇸
Parexel Early Phase Clinical Unit, Glendale, California, United States

Addition of Probenecid to Penicillin-V Therapy

Phase 1

Completed

Conditions: Infection, Bacterial

Interventions: Drug: Probenecid

First Posted Date: 2021-10-19

Last Posted Date: 2025-01-30

Lead Sponsor: Imperial College London

Target Recruit Count: 21

Registration Number: NCT05082909

Locations: 🇬🇧
Imperial Clinical Research Facility, London, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy